EGFR and hepatocellular carcinoma: Our data showed that HBx overexpression did not alter the cellular sensitivity of HCC cell lines to sorafenib, but unexpectedly enhanced the cell death induced by EGFR family inhibitors through shifting the oncogenic addiction to ErbB2/ErbB3 signaling pathway via enhancing ErbB3 expression.